Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
A commercial environment reinvigorated by improved fundamentals—increased regulatory flexibility and the emergence of exciting new scientific opportunities and innovative business models—has set the stage for a resurgence in the antibiotics space that has already led to an uptick in early-stage venture investment and strategic partnerships.
The dermatology space is emerging from an active period of diversification and consolidation that has opened up new partnering opportunities. Besides the cosmetic market, the medical segment has also entered a growth phase propelled by three indications: melanoma, psoriasis and systemic lupus erythematosus.
Building on the huge success of monoclonal antibody therapeutics, the next generation of antibody-based products such as bispecifics and antibody-drug conjugates is now opening up new opportunities.
Valuations and volume are up in a buoyant year for biopharmaceutical dealmaking. From tax inversions to gene therapy and, of course, immuno-oncology, 2014 and early 2015 featured plenty of wheeling and dealing.
Today, academic-industrial partnerships are part of an integrated development strategy for any of the world’s top ten pharmaceutical companies and a growing number of academic institutions.
Regenerative medicine and advanced technologies make up a diverse group of therapeutics. As curative strategies for treating disease, they have the potential to alter the standard of care for many indications. With associated risks now tempered, investors and big pharma are showing interest.
Next-generation sequencing platforms are building market share not only in the research setting but also increasingly in population research and clinical applications.
Venture capital investment in devices remains lackluster, but megamergers and startups in digital health, drug delivery and minimally invasive technology are providing new impetus to today’s evolving medical technology industry.
After a period of setbacks and the exodus of high-profile companies from neuroscience research and development, industry leaders predict a rebound in neuroscience investment and deal activity in areas such as pain.
Big pharma’s interest in the therapeutic potential of modulating the body’s own bacterial ecosystem is growing, particularly with regard to the treatment of inflammatory disorders.
Although specific age-related disorders such as Alzheimer’s disease continue to be a focus of research and development investment and dealmaking activity, companies are also beginning to approach aging in a broader way.
